Microbiotica Entered into a Clinical Trial Collaboration Agreement with MSD to Evaluate MB097 + Keytruda (pembrolizumab) for Melanoma
- The companies collaborated to conduct the P-I trial evaluating the safety tolerability & initial signs of clinical activity of MB097 + Keytruda in patients with melanoma
- Microbiotica will be the study sponsor & MSD will be responsible to supply Keytruda. MB097 is an orally administered live biotherapeutic product consisting of a defined consortium of 9 bacterial strains. The goal of MB097 is to increase the effectiveness of ICIs
- In in vivo tumor models, MB097 showed strong anti-tumor efficacy when combined with ICIs. It also showed multiple immuno-stimulatory mechanisms in primary human immune cell assays, incl. activation of cytotoxic T lymphocytes & in vitro tumor cell eradication
Ref: Businesswire | Image: Microbiotica
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.